|
1
|
Key Statistics for Prostate Cancer |
Prostate Cancer Facts.
|
|
2
|
Kume H, Kawai T, Nagata M, Azuma T,
Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H and Homma
Y: Intermittent docetaxel chemotherapy is feasible for
castration-resistant prostate cancer. Mol Clin Oncol. 3:303–307.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kharaziha P, Chioureas D, Rutishauser D,
Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev
R, Ullén A, et al: Molecular profiling of prostate cancer derived
exosomes may reveal a predictive signature for response to
docetaxel. Oncotarget. 6:21740–21754. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ratnayake WS and Acevedo-Duncan M:
Abstract 4569: Use of ACPD and ICA-1 as inhibitors of atypical
proteinkinase C-zeta (ζ) and iota (ι) in metastasized melanoma
cells. Cancer Res. 76:4569. 2016.
|
|
5
|
Ratnayake WS and Acevedo-Duncan M:
Abstract 862: Atypical protein kinase c inhibitors can repress
epithelial to mesenchymal transition (type III) in malignant
melanoma. Cancer Res. 77:862. 2017.
|
|
6
|
Ratnayake WS, Apostolatos CA and
Acevedo-Duncan M: Atypical protein kinase cs in melanoma
progression. Cutan Melanoma, 2019.
|
|
7
|
Apostolatos AH, Ratnayake WS, Smalley T,
Islam A and Acevedo-Duncan M: Abstract 2369: Transcription
activators that regulate PKC-iota expression and are downstream
targets of PKC-iota. Cancer Res. 77:2369. 2017.
|
|
8
|
Ratnayake WS, Apostolatos AH, Ostrov DA
and Acevedo-Duncan M: Two novel atypical PKC inhibitors; ACPD and
DNDA effectively mitigate cell proliferation and epithelial to
mesenchymal transition of metastatic melanoma while inducing
apoptosis. Int J Oncol. 51:1370–1382. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ratnayake WS, Apostolatos CA, Apostolatos
AH, Schutte RJ, Huynh MA, Ostrov DA and Acevedo-Duncan M: Oncogenic
PKC-ι activates Vimentin during epithelial-mesenchymal transition
in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors.
Cell Adhes Migr. 12:447–463. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Apostolatos AH, Ratnayake WS, Win-Piazza
H, Apostolatos CA, Smalley T, Kang L, Salup R, Hill R and
Acevedo-Duncan M: Inhibition of atypical protein kinase C-ι
effectively reduces the malignancy of prostate cancer cells by
downregulating the NF-κB signaling cascade. Int J Oncol.
53:1836–1846. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ratnayake W: Role of oncogenic protein
kinase C-iota in melanoma progression; A study based on atypical
protein kinase-C inhibitors (unpublished PhD thesis). University of
South Florida, 2019.
|
|
12
|
Manning G, Whyte DB, Martinez R, Hunter T
and Sudarsanam S: The protein kinase complement of the human
genome. Science. 298:1912–1934. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Regala RP, Weems C, Jamieson L, Khoor A,
Edell ES, Lohse CM and Fields AP: Atypical protein kinase C iota is
an oncogene in human non-small cell lung cancer. Cancer Res.
65:8905–8911. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dey A, Patel R, Smalley T, Ratnayake WS,
Islam A and Acevedo-Duncan M: Abstract 244: Inhibition of atypical
PKC signaling enhances the sensitivity of glioblastoma cells
towards Temozolomide therapy. Cancer Res. 79:244. 2019.
|
|
15
|
Wu J, Lu M, Li Y, Shang YK, Wang SJ, Meng
Y, Wang Z, Li ZS, Chen H, Chen ZN and Bian H: Regulation of a
TGF-β1-CD147 self-sustaining network in the differentiation
plasticity of hepatocellular carcinoma cells. Oncogene.
35:5468–5479. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Venter JC, Adams MD, Myers EW, Li PW,
Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al:
The Sequence of the human genome. Science. 291:1304–1351.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fagerberg L, Hallström BM, Oksvold P,
Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S,
Danielsson A, Edlund K, et al: Analysis of the human
tissue-specific expression by genome-wide integration of
transcriptomics and antibody-based proteomics. Mol Cell Proteomics.
13:397–406. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ratnayake W, Apostolatos C, Breedy S,
Apostolatos A and Acevedo-Duncan M: FOXO1 regulates oncogenic PKC-ι
expression in melanoma inversely to c-Jun in an autocrine manner
via IL-17E and ICAM-1 activation. World Acad Sci J. 1:25–38.
2018.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Butler AM, Buzhardt MLS, Erdogan E, Li S,
Inman KS, Fields AP and Murray NR: A small molecule inhibitor of
atypical protein kinase C signaling inhibits pancreatic cancer cell
transformed growth and invasion. Oncotarget. 6:15297–15310.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wisdom R, Johnson RS and Moore C: c-Jun
regulates cell cycle progression and apoptosis by distinct
mechanisms. EMBO J. 18:188–197. 1999.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Angel P, Hattori K, Smeal T and Karin M:
The jun proto-oncogene is positively autoregulated by its product,
Jun/AP-1. Cell. 55:875–885. 1988.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lopez-Bergami P, Huang C, Goydos JS, Yip
D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson
S and Ronai Z: Rewired ERK-JNK signaling pathways in melanoma.
Cancer Cell. 11:447–460. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vogt PK: Fortuitous convergences: The
beginnings of JUN. Nat Rev Cancer. 2:465–469. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Szabo E, Riffe ME, Steinberg SM, Birrer MJ
and Linnoila RI: Altered cJUN expression: An early event in human
lung carcinogenesis. Cancer Res. 56:305–315. 1996.PubMed/NCBI
|
|
26
|
Vleugel MM, Greijer AE, Bos R, van der
Wall E and van Diest PJ: c-Jun activation is associated with
proliferation and angiogenesis in invasive breast cancer. Hum
Pathol. 37:668–674. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Behrens A, Sibilia M and Wagner EF:
Amino-terminal phosphorylation of c-Jun regulates stress-induced
apoptosis and cellular proliferation. Nat Genet. 21:326–329.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Nateri AS, Spencer-Dene B and Behrens A:
Interaction of phosphorylated c-Jun with TCF4 regulates intestinal
cancer development. Nature. 437:281–285. 2005.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rena G, Guo S, Cichy SC, Unterman TG and
Cohen P: Phosphorylation of the transcription factor forkhead
family member FKHR by protein kinase B. J Biol Chem.
274:17179–17183. 1999.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nakae J, Kitamura T, Kitamura Y, Biggs WH,
Arden KC and Accili D: The forkhead transcription factor foxo1
regulates adipocyte differentiation. Dev Cell. 4:119–129.
2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Matsuzaki H, Daitoku H, Hatta M, Tanaka K
and Fukamizu A: Insulin-induced phosphorylation of FKHR (Foxo1)
targets to proteasomal degradation. Proc Natl Acad Sci USA.
100:11285–11290. 2003.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lu H and Huang H: FOXO1: A potential
target for human diseases. Curr Drug Targets. 12:1235–1244.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Borkhardt A, Repp R, Haas OA, Leis T,
Harbott J, Kreuder J, Hammermann J, Henn F, Lampert T, Harbott J,
et al: Cloning and characterization of AFX, the gene that fuses to
MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene.
14:195–202. 1997.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Anderson MJ, Viars CS, Czekay S, Cavenee
WK and Arden KC: Cloning and characterization of three human
forkhead genes that comprise an FKHR-like gene subfamily. Genomics.
47:187–199. 1998.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fu Z and Tindall D: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang Y, Zhang L, Sun H, Lv Q, Qiu C, Che
X, Liu Z and Jiang J: Forkhead transcription factor 1 inhibits
endometrial cancer cell proliferation via sterol regulatory
element-binding protein 1. Oncol Lett. 13:731–737. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yue P and Turkson J: Targeting STAT3 in
cancer: How successful are we? Expert Opin Investig Drugs.
18:45–56. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jing N and Tweardy DJ: Targeting Stat3 in
cancer therapy. Anticancer Drugs. 16:601–607. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Page BDG, Khoury H, Laister RC, Fletcher
S, Vellozo M, Manzoli A, Yue P, Turkson M, Minden MD and Gunning
PT: Small molecule STAT5-sh2 domain inhibitors exhibit potent
antileukemia activity. J Med Chem. 55:1047–1055. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pardanani A, Lasho T, Smith G, Burns CJ,
Fantino E and Tefferi A: CYT387, a selective JAK1/JAK2 inhibitor:
In vitro assessment of kinase selectivity and preclinical studies
using cell lines and primary cells from polycythemia vera patients.
Leukemia. 23:1441–1445. 2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rani A and Murphy JJ: STAT5 in cancer and
immunity. J Interferon Cytokine Res. 36:226–237. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Korneev KV, Atretkhany KSN, Drutskaya MS,
Grivennikov SI, Kuprash DV and Nedospasov SA: TLR-signaling and
proinflammatory cytokines as drivers of tumorigenesis. Cytokine.
89:127–135. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang X, Wrzeszczynska MH, Horvath CM and
Darnell JE: Interacting regions in stat3 and c-jun that participate
in cooperative transcriptional activation. Mol Cell Biol.
19:7138–7146. 1999.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hornsveld M, Dansen TB, Derksen PW and
Burgering BMT: Re-evaluating the role of FOXOs in cancer. Semin
Cancer Biol. 50:90–100. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sunters A, Madureira PA, Pomeranz KM,
Aubert M, Brosens JJ, Cook SJ, Burgering BMT, Coombes RC and Lam
EWF: Paclitaxel-induced nuclear translocation of FOXO3a in breast
cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Cancer Res. 66:212–220. 2006.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Yuan ZL, Guan YJ, Wang LW, Wei W, Kane AB
and Chin YE: Central role of the threonine residue within the p+1
loop of receptor tyrosine kinase in STAT3 constitutive
phosphorylation in metastatic cancer cells. Mol Cell Biol.
24:9390–9400. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Antonicelli F, Lorin J, Kurdykowski S,
Gangloff SC, Naour RL, Sallenave JM, Hornebeck W, Grange F and
Bernard P: CXCL10 reduces melanoma proliferation and invasiveness
in vitro and in vivo. Br J Dermatol. 164:720–728. 2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zaynagetdinov R, Sherrill TP, Gleaves LA,
McLoed AG, Saxon JA, Habermann AC, Connelly L, Dulek D, Peebles RS
Jr, Fingleton B, et al: Interleukin-5 facilitates lung metastasis
by modulating the immune microenvironment. Cancer Res.
75:1624–1634. 2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Ishiguro H, Akimoto K, Nagashima Y, Kojima
Y, Sasaki T, Ishiguro-Imagawa Y, Nakaigawa N, Ohno S, Kubota Y and
Uemura H: aPKClamda/iota promotes growth of prostate cancer cells
in an autocrine manner through transcriptional activation of
interleukin-6. Proc Natl Acad Sci USA. 106:16369–16374.
2009.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Peng H, Chen P, Cai Y, Chen Y, Wu QH, Li
Y, Zhou R and Fang X: Endothelin-1 increases expression of
cyclooxygenase-2 and production of interlukin-8 in hunan pulmonary
epithelial cells. Peptides. 29:419–424. 2008.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Timani KA, Győrffy B, Liu Y, Mohammad KS
and He JJ: Tip110/SART3 regulates IL-8 expression and predicts the
clinical outcomes in melanoma. Mol Cancer. 17(124)2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yang M, Liu J, Piao C, Shao J and Du J:
ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2
polarization through blockade of efferocytosis. Cell Death Dis.
6(e1780)2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Groote ML, de Kazemier HG, Huisman C, Gun
BTF, van der Faas MM and Rots MG: Upregulation of endogenous ICAM-1
reduces ovarian cancer cell growth in the absence of immune cells.
Int J Cancer. 134:280–290. 2014.PubMed/NCBI View Article : Google Scholar
|
